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Objective: To explore the mechanism of all-transretinoic acid (ATRA) increasing reti-
noblastoma (RB) sensitivity to vincristine, and the inhibiting effect of vincristine com-
bined with ATRA treatment on the SO-RB50 cell proliferation.
Methods: SO-RB50 cells were cultivated by routine culture method. Different concen-
trations of vincristine or ATRA were added into culture solution. After 48 h, cell counting
kit-8 was used to detect the median inhibitory concentration (IC50) of vincristine com-
bined with ATRT treatment to SO-RB50 cells. SO-RB50 cells were divided into drug
combination group, vincristine group, ATRA group and control group. Different drugs
were added into the culture solution respectively for cell culture based on the IC50 value.
Cell counting kit-8 was used to detect the cell proliferation every 24-h cultivation. After
continuous determination for 6 d, data was processed to draw the cell growth curve. After
drug use for 72 h, ﬂow cytometry was used to detect the proportion of different cell cycles
of SO-RB50 cells in each group. After drug use for 48 h, annexin V/propidium iodide
method was used to detect the SO-RB50 cell apoptosis in each group.
Results: The IC50 value of vincristine treatment on the SO-RB50 cells was 0.11 mmol/L,
and ATRT was 12.84 mmol/L. The cell growth curve in control group rose gradually
along with the extended culture time, but after vincristine and ATRA treatment, the cell
growth curve was smooth and steady. The cell increment was the least in drug combi-
nation group and its cell growth curve was the smoothest. There was signiﬁcant differ-
ence in A450 48 h and 72 h after treatment (Fgrouping = 77.316, P < 0.001; Ftime = 86.985,
P < 0.001). Compared with control group, A450 value in drug combination group,
vincristine group, ATRA group was signiﬁcant lower (P < 0.001). Compared with
control group, the G2/M phase cell proportion in vincristine group was signiﬁcantly
increased, while the G0/G1 phase cell proportion was signiﬁcantly decreased; the G0/G1
phase cell proportion in ATRA group was signiﬁcantly increased, while the S phase cell
proportion was signiﬁcantly decreased (FG0/G1 = 85.878, Fs = 56.455, FG2/M = 85.878,
P < 0.001). After 48 h, there was signiﬁcant difference in SO-RB50 cell apoptosis rate
among groups (F = 11.312, P < 0.05). The apoptosis rate in drug combination group was
signiﬁcantly higher than that of other groups (P < 0.001).
Conclusions: ATRA can increase the sensitivity of SO-RB50 cells to vincristine.
Vincristine combined with ATRA treatment can signiﬁcantly increase the inhibiting ef-
fect on SO-RB50 cells, which may be related with promoting cell apoptosis and involving
in cell cycle control.Tong University, Shanghai 200127,
0).
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Retinoblastoma (RB) is a kind of intraocular malignant tu-
mor. Most infants are vulnerable to RB, accounting for 3%–4%
of children's malignant tumors. RB has brought a great threat to
the eyesight and life of children [1]. Survival rate of children
with RB in developed countries is up to 95%, while it is only
50% worldwide [2,3]. Clinical treatments for RB mainly
include chemotherapy, radiotherapy, surgery and other local
treatments [4]. Among them, chemotherapy plays a very
important therapeutic effect. However, the drug resistance of
tumor cells easily leads to the chemotherapy failure [5,6].
Therefore, the research hotspot in this world is focused on
looking for a kind of more sensitive chemotherapy [7]. All-
transretinoic acid (ATRA) can effectively promote the cell dif-
ferentiation and obviously inhibit the cell proliferation [8]. There
are researches showing that ATRA can effectively increase the
sensitivity of multiple tumor cells like breast cancer and liver
cancer to chemotherapies. However, researches on increasing
the sensitivity of RB chemotherapies are relatively less [9,10].
In this study, the mechanism that ATRA could increase the
sensitivity of RB to vincristine and the inhibiting effect of
vincristine combined with ATRA treatment on the SO-
RB50 cell proliferation have been discussed.
2. Meterials and methods
2.1. Materials
2.1.1. Cell sources
SO-RB50 cell lines were provided by Pathology Lab of
Zhongshan Eye Center, Zhongshan University. RPMI/1640
culture solution (containing 1% mass fraction of mycillin anti-
body and 10% volume fraction of fetal calf serum) was used to
culture these cells. Culture condition: temperature (37 C),
saturation humidity and volume fraction (5% CO2). Cells
showed a suspended growth and cells in logarithmic phase were
selected for detection.
2.1.2. Key instruments and reagents
CO2 incubator was from Japan SANYO Co.; ELIASA was
from Beijing Perlong New counting Co., Ltd.; ﬂow cytometry
(FCM) was from America BD Co. RPMI/1640 culture medium
and fetal calf serum were from America Hyclone Co.; ATRA
was from America Sigma Co.; vincristine was from Zhejiang
Hisun Pharmaceutical Company Ltd.; cell apoptosis detection
kit was from Beijing 4A Biotech Co., Ltd.; cell counting kit-8
(CCK-8) was from Japan Dojindo Co.; cell cycle detection kit
was from Hangzhou MultiSciences Biotech Co., Ltd.
2.2. Methods
2.2.1. IC50 value of SO-RB50 cells after vincristine and
ATRA treatment detected by CCK-8
SO-RB50 cells in logarithmic phase were inoculated into 96-
well culture plates evenly, with 5000/hole. Different mass
concentrations of 0.005, 0.010, 0.050, 0.100, 0.500 and
1.000 mmol/L of vincristine and 2.50, 5.00, 10.00, 20.00 and
40.00 mmol/L of ATRA were added respectively. A total of 5
holes were set up for each concentration. After being cultured
for 48 h, 10 mL of CCK-8 reagent was added into each hole for2 h incubation at 37 C. ELIASA method was used to detect the
A450 value at 450 nm [11].
2.2.2. Cell proliferation detected by CCK-8
The cultured cells were divided into drug combination
group, vincristine group, ATRA group and control group. SO-
RB50 cells in logarithmic phase were inoculated into 96-well
culture plates, with 2.5 × 104/mL of density. A total of
200 mL was added into each hole. IC450 of vincristine
(0.11 mg/mL) or ATRA (12.84 mmol/L) was added respec-
tively according to the grouping. Five holes were set up in
each group. CCK-8 was used to detect the A450 value of cells
in each group at 450 nm every 24 h for 6 continuous days.
Then the average value was calculated and the cell growth
curve was drew [12].
2.2.3. Cell cycle detected by FCM
SO-RB50 cells in logarithmic phase were inoculated into six-
well culture plates, with 2.5 × 104/mL of density. Each hole was
inoculated with 2 mL. IC450 of vincristine or ATRA was added
respectively. A total of 72 h after drug treatment, PBS was used
for washing for 2 times, with centrifugation for 5 min (1000 r/
min and 12 cm of centrifugal radius). A total of 1 × 106 cells
were collected in each group and were ﬁxed with ethyl alcohol
with 70% of volume fraction. Temperature was controlled at
4 C and treatment was performed after overnight. After PBS
washing for once, 100 mL of buffer solution (containing 100 mg/
mL of RNA enzyme and 0.2% volume fraction of Triton X-100)
was added for 30 min incubation at 37 C; then 400 mL of
propidium iodide (PI) staining solution was added for 30 min
incubation at 4 C, with keeping out of the sun. FCM was
performed to detect the cells of different cell cycles. Cell pro-
portion was calculated [13].
2.2.4. Apoptosis rate of cells detected by annexin V/PI
SO-RB50 cells in logarithmic phase were inoculated into six-
well culture plates, with 2.5 × 104/mL of density. Each hole was
inoculated with 2 mL. IC450 of vincristine or ATRA was added
respectively. A total of 72 h after drug treatment, PBS was used
for washing for 2 times, with centrifugation for 5 min (1000 r/
min). A total of 1 × 106 cells were collected in each group. A
total of 100 mL of binding buffer solution was added for cell
resuspension. Then 10 mL of annexin V-FITC and 5 mL of PI
were added into culture solution for mixing, with incubation for
30 min at 4 C. Afterwards, incubation for 15 min was per-
formed with keeping out of the sun and 400 mL of binding buffer
solution was added once more. FCM was used to make a
comparison of the ratio of apoptotic cells [14].
2.3. Statistical method
SPSS 13.0 statistical package was used for experimental data
analysis. The data information in this study showed a normal
distribution by Shapiro–Wilk test. Data was expressed by
mean ± SD and was detected by Levene homogeneity test of
variances. Grouping was based on the balanced grouping and
multilevel experimental design method. Block design two-way
analysis of variance (ANOVA) was adopted to compare the
overall difference of A450 value changes in different time in drug
combination group, vincristine group, ATRA group and control
group. SNK-q test was used for multiple comparisons among
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centage and apoptosis rate in different cell cycles in each group.
When P < 0.05, the difference had statistical signiﬁcance.
3. Results
3.1. IC50 value of vincristine and ATRA treatment for
SO-RB50 cells
The SO-RB50 cells were treated with different concentra-
tions of vincristine working solutions, respectively, and the cell
proliferation inhibition rate was measured and IC50 value of
vincristine calculated. The SO-RB50 cells were treated with
different concentrations of ATRA, respectively, and the cell
proliferation inhibition rate was measured and IC50 value of
ATRA calculated. The results were shown in Table 1.
3.2. Cell proliferation in each group
Vincristine and ATRA treatment was performed respectively
for SO-RB50 cells for 6 d. The change in cell growth rate with
time in control group was signiﬁcantly larger than that in
vincristine group, ATRA group and drug combination group,
and that in drug combination group was the minimum. There
were signiﬁcant difference in cell proliferation rates among the
4groups 48 h and 72 h after drug treatment (P < 0.001). A total
of 48 h after drug treatment, compared with vincristine group,Table 1
IC50 values of vincristine and ATRA for SO-RB50 cells.
Vincristine group Concentrations (mg/mL) 0.005
Cell proliferation inhibition rate (%) 12.52
ATRA group Concentrations (mmol/L) 2.50
Cell proliferation inhibition rate (%) 8.57
Table 2
Cell proliferation in each group.
Group 1 d 2 d
Drug combination group 0.392 ± 0.026 0.482 ± 0.029 0.531
Vincristine group 0.392 ± 0.026 0.594 ± 0.030a 0.667
ATRA group 0.392 ± 0.026 0.612 ± 0.037a 0.798
Control group 0.392 ± 0.026 1.079 ± 0.023a 1.380
F – 77.316 86.98
P – <0.001 <0.0
Compared with drug combination group, aP < 0.001.
Table 3
Proportion of SO-RB50 cells in different cell cycles 72 h after drug treatme
Group Sample size
G0/G1
Drug combination 3 69.373 ± 0.7
Vincristine 3 71.268 ± 0.1
ATRA 3 87.452 ± 2.2
Control 3 75.804 ± 0.7
F 85.878
P <0.001
Compared with control group, a P < 0.001; compared with ATRA group, bATRA group and control group, A450 value in drug combination
group was signiﬁcantly lower (P < 0.001) (Table 2).
3.3. Proportion of SO-RB50 cells in different cell cycles
72 h after drug treatment
There were signiﬁcant differences in proportion changes of
SO-RB50 cells in G0/G1 phase, G2/M phase, S phase 72 h after
treatment of different drugs (F = 130.565, F = 114.290,
F = 57.435; P < 0.001). The G0/G1 phase cell proportion in
vincristine group was signiﬁcantly reduced; G2/M cell propor-
tion was signiﬁcantly increased (P < 0.001). The G0/G1 phase
cell proportion in ATRA group was signiﬁcantly higher than that
in control group; S phase cell proportion was signiﬁcantly lower
than that in control group (P < 0.001). The results were shown
in Table 3.
3.4. Apoptosis rate of SO-RB50 cells in each group 48 h
after treatment of different drugs
A total of 48 h after different drug treatment, there was
signiﬁcant difference in apoptosis rate of SO-RB50 cells among
four groups (P < 0.05). Compared with control group, the
apoptosis rate in drug combination group, vincristine group and
ATRA group were signiﬁcantly higher (P < 0.001). Compared
with vincristine group and ATRA group, the apoptosis rate in
drug combination group was signiﬁcantly higher (P < 0.001).0.010 0.050 0.100 0.500 1.000 IC50 value
22.57 39.73 53.68 67.00 73.93 0.11 mg/mL
5.00 10.00 20.00 40.00 IC50 value
31.23 49.86 65.04 70.01 12.84 mg/mL
3 d 4 d 5 d 6 d
± 0.035 0.546 ± 0.032 0.550 ± 0.036 0.564 ± 0.031
± 0.039a 0.724 ± 0.032a 0.733 ± 0.030a 0.740 ± 0.035a
± 0.017a 0.831 ± 0.018a 0.831 ± 0.018a 0.831 ± 0.018a
± 0.022a 1.479 ± 0.023a 1.782 ± 0.025a 2.397 ± 0.026a
5
01 <0.001 <0.001 <0.001
nt.
Cells in different cell cycles
G2/M S
47ab 15.522 ± 1.255b 15.101 ± 0.556ab
38ab 14.512 ± 0.895b 14.214 ± 0.801ab
24a 5.872 ± 1.399a 6.680 ± 0.942
26 15.939 ± 0.636 7.921 ± 0.305
64.547 56.455
<0.001 <0.001
P < 0.001 (one-way ANOVA, SNK-q test).
Table 4
Apoptosis rate of SO-RB50 cells in each group 48 h after drug treatment.
Group Apoptosis rate (%)
Drug combination group 34.50 ± 1.86ab
Vincristine group 27.47 ± 2.46ac
ATRA group 27.33 ± 1.38ac
Control group 7.18 ± 0.17bc
F 11.312
P <0.001
Compared with control group, aP < 0.001; compared with ATRA group,
bP < 0.001; compared with drug combination group, cP < 0.001 (one-
way ANOVA, SNK-q test).
Yan Jiang, Lin Zhang/Asian Paciﬁc Journal of Tropical Medicine 2016; 9(3): 278–282 281There was no signiﬁcant difference in the apoptosis rate between
vincristine group and ATRA group (P = 0.919) (Table 4).
4. Discussion
In recent years, the therapeutic goal for RB have changed
from increasing the survival rate of children to the living
quality of children. The treatment mode has also changed
gradually from eyeball extraction to conservative treatment
[15,16]. Chemotherapies in clinic could increase the retention
rate of eyeballs in a certain degree, but the drug resistance
of tumor cells to the traditional drugs of chemotherapies
would easily lead to the treatment failure [17]. At present,
research hotspots are focused on looking for effective
chemosensitizer.
There were researches showing that ATRA could effectively
increase the chemical sensibility of multiple tumors [18,19].
Through experiments in vitro and vivo, researchers found that
ATRA could effectively induce the liver cancer stem cell
differentiation and increase the sensitivity of tumor cells to
cis-platinum [20]. Through phase II clinic trial, it was found
that ATRA combined with paclitaxel or cis-platinum could
increase the efﬁcacy of patients with advanced non-small cell
lung cancer [21]. There were reports showing that ATRA
combined with paclitaxel could relieve the metastatic or
recurrent breast cancer in a certain degree and bring better
tolerance for patients [22,23]. In this study, the effect of the
sensitivity of ATRA to vincristine, the typical chemotherapy
drug for RB, was mainly discussed. Research results showed
that ATRA combined with vincristine treatment had obvious
inhibiting effects and apoptosis-promoting effects on the SO-
RB50 cell proliferation, and the efﬁcacy of the combined drugs
was obviously better than single drug use of vincristine. That
was to say, ATRA could obviously increase the sensitivity of
SO-RB50 cells to vinblastine.
Vitamin A metabolism in vivo could produce ATRA and
ATRA combined with cell receptor could regulate and control
the gene expression, and then promote the cell differentiation
and inhibit the cell proliferation [24]. There were researches
showing that ATRA could effectively inhibit the proliferation
of multiple tumors, like RB, glioma, leukemia, and
neuroblastoma [25]. In this research, CCK-8 detection method
was adopted to prove the fact that ATRA could inhibit the cell
growth, after playing effects, G0/G1 phase SO-RB50 cells were
obviously increased; while S phase SO-RB50 cells were obvi-
ously decreased. ATRA could make cell stasis at G0/G1 phase
and then slower the cell growth speed, which was in accordance
with the previous reports [26,27]. Vincristine was a kind of cellmitosis inhibitor, action mechanism of which was that
vincristine combined with microtubulin speciﬁcally could
block the microtubule formation and result in the stasis of cell
division at the metaphase [28]. This research indicated that
after vincristine treatment, SO-RB50 cells at G0/G1 phase were
obviously reduced; while SO-RB50 cells at G2/M phase were
obviously increased, which was in accordance with the
previous reports that vincristine could produce periodic
blocking to neuroblastoma [29,30]. Its mechanism was that
vincristine was a key factor resulting in the cell cycle changes.
Vincristine and ATRA could effectively play inhibiting effects
on cell proliferation for different phase of cells. In addition, in
this study, also it was also found that ATRA could increase
the apoptosis rate of cells, which indicated that ATRA might
induce the cell apoptosis and then play inhibiting effects on
cell proliferation.
In conclusion, through experiments in vitro in this study, it
was proved that ATRA can effectively increase the sensitivity of
SO-RB50 cells to vincristine, which provide theoretical basis for
exploring new drug combination scheme for neuroblastoma. The
possible mechanism of that includes inducing the cell apoptosis,
and regulating and controlling the cell cycle. In addition, further
research is necessary to discuss other possible action
mechanism.
Conﬂict of interest statement
We declare that we have no conﬂict of interest.
References
[1] Steinmetz B, Hackl H, Slaba´kova´ E, Schwarzinger I, Smejova´ M,
Spittler A, et al. The oncogene EVI1 enhances transcriptional and
biological responses of human myeloid cells to all-trans retinoic
acid. Cell Cycle 2014; 13(18): 2931-2943.
[2] Yang F, He Y, Liu HX, Tsuei J, Jiang X, Yang L, et al. All-trans
retinoic acid regulates hepatic bile acid homeostasis. Biochem
Pharmacol 2014; 91(4): 483-489.
[3] Komori R, Kobayashi T, Matsuo H, Kino K, Miyazawa H. Csn3
gene is regulated by all-trans retinoic acid during neural differen-
tiation in mouse P19 cells. PloS One 2013; 8(4): e61938; http://
dx.doi.org/10.1371/journal.pone.0061938.
[4] Zhan XX, Liu Y, Yang JF, Wang GY, Mu L, Zhang TS, et al. All-
trans-retinoic acid ameliorates experimental allergic encephalo-
myelitis by affecting dendritic cell and monocyte development.
Immunology 2013; 138(4): 333-345.
[5] Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, et al. High
efﬁcacy of arsenic trioxide plus all-trans retinoic acid based in-
duction and maintenance therapy in newly diagnosed acute pro-
myelocytic leukemia. Leuk Res 2013; 37(1): 37-42.
[6] Masetti R, Vendemini F, Zama D, Biagi C, Gasperini P, Pession A.
All-trans retinoic acid in the treatment of pediatric acute promyelocytic
leukemia. Expert Rev Anticancer Ther 2012; 12(9): 1191-1204.
[7] Lei GS, Zhang C, Shao S, Jung HW, Durant PJ, Lee CH. All-trans
retinoic acid in combination with primaquine clears Pneumocystis
infection. PloS One 2013; 8(1): e53479; http://dx.doi.org/10.1371/
journal.pone.0053479.
[8] Rubin SM. Deciphering the retinoblastoma protein phosphoryla-
tion code. Trends Biochem Sci 2013; 38(1): 12-19.
[9] Ajioka I. Coordination of proliferation and neuronal differentiation
by the retinoblastoma protein family. Dev Growth Differ 2014;
56(5): 324-334.
[10] Houston SK, Murray TG. Microarray gene-expression analysis in
ocular oncology: uveal melanoma and retinoblastoma. Expert Rev
Ophthalmol 2014; 6(4): 477-485.
Yan Jiang, Lin Zhang/Asian Paciﬁc Journal of Tropical Medicine 2016; 9(3): 278–282282[11] Zhu SJ, Pearson BJ. The retinoblastoma pathway regulates stem
cell proliferation in freshwater planarians. Dev Biol 2013; 373(2):
442-452.
[12] Kapatai G, Brundler MA, Jenkinson H, Kearns P, Parulekar M,
Peet AC. Gene expression proﬁling identiﬁes different sub-types of
retinoblastoma. Br J Cancer 2013; 109(2): 512-525.
[13] Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T,
Cheng P, et al. Epigenetic silencing of retinoblastoma gene regu-
lates pathologic differentiation of myeloid cells in cancer. Nat
Immunol 2013; 14(3): 211-220.
[14] Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P,
Schwartz GF, et al. The retinoblastoma tumor suppressor pathway
modulates the invasiveness of ErbB2-positive breast cancer.
Oncogene 2014; 33(30): 3980-3991.
[15] Philippeit C, Busch M, Du¨nker N. Epigenetic control of trefoil
factor family (TFF) peptide expression in human retinoblastoma
cell lines. Cell Physiol Biochem 2014; 34(3): 1001-1014.
[16] Chawla B, Jain A, Azad R. Conservative treatment modalities in
retinoblastoma. Indian J Ophthalmol 2013; 61(9): 479-485.
[17] Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome
injection) improves the pharmacokinetics and pharmacodynamics
of vincristine. Cancer Chemoth Pharm 2013; 71(3): 555-564.
[18] Dun L, Li Y, Xu Y, Zhou R, Ma L, Jin S, et al. Antinociceptive
effect of matrine on vincristine-induced neuropathic pain model in
mice. Neurol Sci 2014; 35(6): 815-821.
[19] Lewin J, Wieringa S, Collins M, Desai J, Orme L, Lingaratnam S,
et al. Intra-patient dose escalation in Ewing's sarcoma treated with
vincristine, doxorubicin, cyclophosphamide alternating with ifos-
famide and etoposide: a retrospective review. Clin Sarcoma Res
2013; 3(1): 15.
[20] LaPointe NE, Morﬁni G, Brady ST, Feinstein SC, Wilson L,
Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabe-
pilone on fast axonal transport and kinesin-1 driven microtubule
gliding: implications for chemotherapy-induced peripheral neu-
ropathy. Neurotoxicology 2013; 37: 231-239.
[21] Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C,
Brachman DG, et al. Beneﬁt from procarbazine, lomustine, andvincristine in oligodendroglial tumors is associated with mutation
of IDH. J Clin Oncol 2014; 32(8): 783-790.
[22] Cunningham D, Hawkes A, Jack A, Qian W, Smith P, Mouncey P,
et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisolone in patients with newly diagnosed diffuse large B-
cell non-Hodgkin lymphoma: a phase 3 comparison of dose
intensiﬁcation with 14-day versus 21-day cycles. Lancet 2013;
381(9880): 1817-1826.
[23] Kapinas K, Grandy R, Ghule P, Medina R, Becker K, Pardee A,
et al. The abbreviated pluripotent cell cycle. J Cell Physiol 2013;
228(1): 9-20.
[24] Patrício P, Mateus-Pinheiro A, Sousa N, Pinto L. Re-cycling par-
adigms: cell cycle regulation in adult hippocampal neurogenesis
and implications for depression.Mol Neurobiol 2013; 48(1): 84-96.
[25] Noatynska A, Tavernier N, Gotta M, Pintard L. Coordinating cell
polarity and cell cycle progression: what can we learn from ﬂies
and worms? Open Biol 2013; 3(8); http://dx.doi.org/10.1098/
rsob.130083. 130083.
[26] Weinstein N, Ortiz-Gutie´rrez E, Muñoz S, Rosenblueth DA,
A´lvarez-Buylla ER, Mendoza L. A model of the regulatory
network involved in the control of the cell cycle and cell differ-
entiation in the Caenorhabditis elegans vulva. BMC Bioinforma
2015; 16: 81; http://dx.doi.org/10.1186/s12859-015-0498-z.
[27] Arlt A, Mu¨erko¨ster SS, Scha¨fer H. Targeting apoptosis pathways in
pancreatic cancer. Cancer Lett 2013; 332(2): 346-358.
[28] Zeestraten ECM, Benard A, Reimers MS, Schouten PC, Liefers GJ,
Cornelis JH, et al. The prognostic value of the apoptosis pathway in
colorectal cancer: a review of the literature on biomarkers identiﬁed
by immunohistochemistry. Biomark Cancer 2013; 5: 13-29.
[29] Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalco-
holic fatty liver disease: diagnostic and therapeutic implications.
Expert Rev Gastroenterol Hepatol 2011; 5(2): 201-212.
[30] Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mecha-
nisms of UV-induced apoptosis and its effects on skin residential
cells: the implication in UV-based phototherapy. Int J Mol Sci
2013; 14(3): 6414-6435.
